comparemela.com

Page 7 - Akeso Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy -January 27, 2024 at 10:01 am EST

KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC Late-breaking OS results selected for the official.

United statesTonik choueiriNancy kohlbergHarvard medical schoolExchange commissionAsco gu press programDana farber cancer instituteLank centerAmerican society of clinical oncologyStatement of merck co incMerck research laboratoriesEuropean unionAkeso incMerck co incClinical oncologyCancers symposium

Merck s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Region

RAHWAY, N.J. (BUSINESS WIRE) Jan 27, 2024

United statesMichael mcardlePeter dannenbaumDamini chokshiNancy kohlbergTonik choueiriJulie cunninghamAkeso incDana farber cancer instituteStatement of merck co incEuropean unionAsco gu press programMerck co incMerck research laboratoriesExchange commissionLank center

Merck s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Business

RAHWAY, N.J. (BUSINESS WIRE) Jan 27, 2024

United statesPeter dannenbaumDamini chokshiTonik choueiriMichael mcardleNancy kohlbergJulie cunninghamMerck research laboratoriesExchange commissionHarvard medical schoolLank centerAmerican society of clinical oncologyDana farber cancer instituteEuropean unionAkeso incStatement of merck co inc

NMPA Approval Sought for Frontline Cadonilimab Plus Chemo in Gastric or GEJ Adenocarcinoma

China’s National Medical Products Administration has accepted the supplemental new drug application seeking the approval of cadonilimab plus chemotherapy for use in the first-line treatment of patients with unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Ji jiafuYu xiaChina national medical products administrationAkeso incUniversity cancer hospitalNational medical products administrationPeking university cancer hospitalCadonilimab plus chemotherapyGastric cancerGastroesophageal junction adenocarcinomaNational medical products administrationPhase 3 ak104 302 trialPhase 3 ak104 303 trialCervical cancer

Akeso to Present at the 42nd Annual J P Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

HONG KONG, Jan. 8, 2024 /PRNewswire/ Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the.

San franciscoUnited statesHong kongMichelle xiaChinese centerAkeso incHealthcare conferenceClinical dataMilestone outlookResponse rateControl rateNear term milestonesDrug evaluationPotential milestonesSummit therapeuticsMain board

vimarsana © 2020. All Rights Reserved.